ClinicalTrials.Veeva

Menu

Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

V

Vincent Kan

Status and phase

Terminated
Phase 4

Conditions

High Altitude Pulmonary Edema

Treatments

Drug: Acetazolamide
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT03490916
H00014860

Details and patient eligibility

About

The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. At least 18 years of age
  2. Able to consent
  3. English speaking
  4. Trekking directly to Everest Base Camp

Exclusion criteria

  1. Age less than 18 years
  2. Non-English speaking
  3. Pregnant
  4. Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
  5. Been on a high-altitude trek 2 weeks prior to this study
  6. Has taken acetazolamide 1 week prior to start of trek
  7. Has a sulfa allergy
  8. Has any type of acute or chronic pulmonary conditions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

18 participants in 2 patient groups, including a placebo group

Acetazolamide normal dose
Experimental group
Description:
One (1) dose of 250mg of Acetazolamide
Treatment:
Drug: Acetazolamide
Placebo
Placebo Comparator group
Description:
One (1) dose of placebo
Treatment:
Drug: Placebo

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems